智通财经网·2026-02-26 11:22Core Insights - The company reported strong financial performance for Q4 2025 and the full year, indicating a significant growth trajectory in the oncology treatment sector [1][2] - The adjusted net profit for Q4 2025 reached approximately $225 million, a year-on-year increase of 1,297%, while the full-year adjusted net profit was about $918 million, marking a return to profitability [1] - The company projects total revenue for 2026 to be between $6.2 billion and $6.4 billion, reflecting continued growth expectations [1] Financial Performance - Global total revenue for Q4 2025 was $1.5 billion, a 33% increase year-on-year; the full-year global total revenue reached $5.3 billion, up 40% [1] - Free cash flow for Q4 2025 was $380 million, an increase of $397 million compared to the same period last year; the full-year free cash flow was $942 million, up $1.6 billion year-on-year [1] Product Performance - The global sales of Baiyueze® (Zebutinib) in Q4 2025 amounted to $1.1 billion, a 38% year-on-year increase; the annual global sales reached $3.9 billion, up 49% [1] - Global sales of Baizean® (Trelatuzumab) for Q4 2025 were $18.2 million, an 18% increase year-on-year; the full-year global sales were $73.7 million, a 19% increase [1] Strategic Positioning - The company emphasizes its strong position as a leader in the global oncology treatment field, supported by a robust and differentiated R&D pipeline [2] - Baiyueze® has established a leading position in the BTK inhibitor market, backed by extensive regulatory approvals and strong clinical efficacy data in chronic lymphocytic leukemia (CLL) [2] - The company is expanding the indications and reimbursement coverage for Baizean® in major global markets, with several late-stage hematologic oncology products nearing commercialization [2]